Intelligent Bio Solutions Inc Financials
Intelligent Bio Solutions Inc (INBS) reported $4.2M in revenue for fiscal year 2026, up 38.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is scaling, but recurring operating losses still require financing to replenish cash and support the balance sheet.
The FY2026 gross-margin expansion did not translate into operating traction: the operating loss widened to$12.6M as SG&A reached$10.5M . Operating cash flow was-$11.9M against a financing inflow of$15.0M , indicating liquidity was replenished externally rather than by operations.
Gross profit reached
The current ratio improved to 1.4x while debt-to-equity fell to 1.2x, indicating less near-term balance-sheet pressure. That improvement does not remove funding dependence: operating cash flow remained
Financial Health Signals
Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Intelligent Bio Solutions Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Intelligent Bio Solutions Inc, and counted as zero in the overall score.
Intelligent Bio Solutions Inc scores -11.02, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($7.5M) relative to total liabilities ($6.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Intelligent Bio Solutions Inc passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Intelligent Bio Solutions Inc reported a net loss of $12.4M while operations used $11.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Intelligent Bio Solutions Inc reported an operating loss of $12.6M against $11K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Intelligent Bio Solutions Inc generated $4.2M in revenue in fiscal year 2026. This represents an increase of 38.1% from the prior year.
Intelligent Bio Solutions Inc's EBITDA was -$11.4M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 17.9% from the prior year.
Intelligent Bio Solutions Inc reported -$12.4M in net income in fiscal year 2026. This represents a decrease of 17.6% from the prior year.
Intelligent Bio Solutions Inc earned -$8.44 per diluted share (EPS) in fiscal year 2026.
Cash & Balance Sheet
Intelligent Bio Solutions Inc recorded an outflow of $12.1M in free cash flow in fiscal year 2026, representing a cash shortfall after capex. This represents a decrease of 21.6% from the prior year.
Intelligent Bio Solutions Inc held $4.0M in cash as of fiscal year 2026; long-term debt is not reported for that period.
Not reported for fiscal year 2026.
Margins & Returns
Intelligent Bio Solutions Inc's gross margin was 48.6% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is up 7.8 percentage points from the prior year.
Intelligent Bio Solutions Inc's ROE was -225.6% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is up 127.2 percentage points from the prior year.
Not shown for fiscal year 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Intelligent Bio Solutions Inc invested $126K in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 45.8% from the prior year.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
INBS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Revenue | $4.2M+38.1% | $3.1M-1.9% | $3.1M+147.6% | $1.3M+187.5% | $437K-77.9% | $2.0M+949.3% | $189K |
| Cost of Revenue | $2.2M+19.9% | $1.8M+7.1% | $1.7M+81.3% | $930K | N/A | N/A | N/A |
| Gross Profit | $2.0M+64.4% | $1.2M-12.5% | $1.4M+336.4% | $327K | N/A | N/A | N/A |
| SG&A Expenses | $10.5M+17.8% | $8.9M-3.7% | $9.3M+15.3% | $8.0M+63.1% | $4.9M+46.5% | $3.4M+52.5% | $2.2M |
| Operating Income | -$12.6M-18.1% | -$10.7M-3.9% | -$10.3M+18.4% | -$12.6M-51.1% | -$8.3M-49.6% | -$5.6M-95.1% | -$2.9M |
| Interest Expense | $11K-59.2% | $26K-84.2% | $167K | N/A | N/A | N/A | N/A |
| Net Income | -$12.4M-17.6% | -$10.6M-4.1% | -$10.2M+4.5% | -$10.6M-28.0% | -$8.3M-18.0% | -$7.0M-122.4% | -$3.2M |
| EPS (Diluted) | -$8.44 | -$20.04 | -$6.38 | -$127.00 | -$11.33 | N/A | N/A |
Not reported in any period shown, so not listed: R&D Expenses, Income Tax.
INBS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Total Assets | $11.9M+44.8% | $8.2M-40.1% | $13.8M+33.1% | $10.4M-16.2% | $12.4M-43.5% | $21.9M+783.0% | $2.5M |
| Current Assets | $7.1M+71.5% | $4.1M-51.5% | $8.5M+120.9% | $3.9M-64.5% | $10.9M-40.3% | $18.2M+678.1% | $2.3M |
| Cash & Equivalents | $4.0M+291.4% | $1.0M-83.8% | $6.3M+310.1% | $1.5M-81.3% | $8.2M-34.5% | $12.6M+2842.8% | $427K |
| Inventory | $419K-34.1% | $635K-18.3% | $778K-20.7% | $980K | N/A | N/A | N/A |
| Accounts Receivable | $848K+42.7% | $595K+38.4% | $430K+46.2% | $294K | N/A | N/A | N/A |
| Total Liabilities | $6.7M+22.4% | $5.4M-2.9% | $5.6M-16.1% | $6.7M+14.8% | $5.8M-15.3% | $6.9M-10.9% | $7.7M |
| Current Liabilities | $4.9M-7.9% | $5.4M-1.8% | $5.5M-7.4% | $5.9M+26.2% | $4.7M+26.6% | $3.7M-52.1% | $7.7M |
| Total Equity | $5.5M+83.9% | $3.0M-64.0% | $8.3M+119.3% | $3.8M-42.7% | $6.6M-56.0% | $15.1M+390.3% | -$5.2M |
| Retained Earnings | -$75.0M-19.9% | -$62.5M-20.3% | -$52.0M-24.3% | -$41.8M-34.1% | -$31.2M-36.3% | -$22.9M-44.4% | -$15.8M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
INBS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$11.9M-23.2% | -$9.7M-1.1% | -$9.6M-29.7% | -$7.4M-119.7% | -$3.4M+70.3% | -$11.3M-2165.6% | -$499K |
| Capital Expenditures | $126K-45.8% | $232K+4.7% | $221K | N/A | N/A | N/A | N/A |
| Free Cash Flow | -$12.1M-21.6% | -$9.9M-1.2% | -$9.8M | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$86K+63.1% | -$232K-4.7% | -$221K+68.1% | -$694K+21.1% | -$880K | N/A | -$14K |
| Financing Cash Flow | $15.0M+225.9% | $4.6M-68.4% | $14.6M+914.4% | $1.4M | N/A | $23.4M+3089.0% | $734K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
INBS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 48.6%+7.8pp | 40.8%-5.0pp | 45.8%+19.8pp | 26.0% | N/A | N/A | N/A |
| Operating Margin | -299.1% | -349.9% | -330.5% | -1002.1% | -1907.1% | -281.4% | -1513.7% |
| Net Margin | -294.9% | -346.2% | -326.4% | -845.9% | -1900.1% | -355.3% | -1676.2% |
| Return on Equity | -225.6%+127.2pp | -352.8%-230.8pp | -121.9%+157.9pp | -279.9%-154.5pp | -125.4%-78.6pp | -46.7% | N/A |
| Return on Assets | -104.1%+24.0pp | -128.1%-54.4pp | -73.7%+29.0pp | -102.7%-35.4pp | -67.2%-35.0pp | -32.2%+95.6pp | -127.8% |
| Current Ratio | 1.44+0.7x | 0.77-0.8x | 1.57+0.9x | 0.66-1.7x | 2.33-2.6x | 4.94+4.6x | 0.30 |
| Debt-to-Equity | 1.21-0.6x | 1.81+1.1x | 0.67-1.1x | 1.76+0.9x | 0.88+0.4x | 0.46 | N/A |
| FCF Margin | -285.9% | -324.6% | -314.7% | N/A | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Intelligent Bio Solutions Inc Ranks
Frequently Asked Questions
What is Intelligent Bio Solutions Inc's annual revenue?
Intelligent Bio Solutions Inc (INBS) reported $4.2M in total revenue for fiscal year 2026. This represents a 38.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Intelligent Bio Solutions Inc's revenue growing?
Intelligent Bio Solutions Inc (INBS) revenue grew by 38.1% year-over-year, from $3.1M to $4.2M in fiscal year 2026.
Is Intelligent Bio Solutions Inc profitable?
No, Intelligent Bio Solutions Inc (INBS) reported a net income of -$12.4M in fiscal year 2026.
What is Intelligent Bio Solutions Inc's EBITDA?
Intelligent Bio Solutions Inc (INBS) had EBITDA of -$11.4M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Intelligent Bio Solutions Inc's gross margin?
Intelligent Bio Solutions Inc (INBS) had a gross margin of 48.6% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Intelligent Bio Solutions Inc's return on equity (ROE)?
Intelligent Bio Solutions Inc (INBS) has a return on equity of -225.6% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Intelligent Bio Solutions Inc's free cash flow?
Intelligent Bio Solutions Inc (INBS) recorded an outflow of $12.1M in free cash flow during fiscal year 2026. This represents a -21.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Intelligent Bio Solutions Inc's operating cash flow?
Intelligent Bio Solutions Inc (INBS) recorded an outflow of $11.9M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Intelligent Bio Solutions Inc's total assets?
Intelligent Bio Solutions Inc (INBS) had $11.9M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Intelligent Bio Solutions Inc's capital expenditures?
Intelligent Bio Solutions Inc (INBS) invested $126K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
What is Intelligent Bio Solutions Inc's current ratio?
Intelligent Bio Solutions Inc (INBS) had a current ratio of 1.44 as of fiscal year 2026, which is considered adequate.
What is Intelligent Bio Solutions Inc's debt-to-equity ratio?
Intelligent Bio Solutions Inc (INBS) had a debt-to-equity ratio of 1.21 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Intelligent Bio Solutions Inc's return on assets (ROA)?
Intelligent Bio Solutions Inc (INBS) had a return on assets of -104.1% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Intelligent Bio Solutions Inc's cash runway?
Based on fiscal year 2026 data, Intelligent Bio Solutions Inc (INBS) had $4.0M in cash against an annual operating cash burn of $11.9M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Intelligent Bio Solutions Inc's Altman Z-Score?
Intelligent Bio Solutions Inc (INBS) has an Altman Z-Score of -11.02, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Intelligent Bio Solutions Inc's Piotroski F-Score?
Intelligent Bio Solutions Inc (INBS) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Intelligent Bio Solutions Inc's earnings high quality?
Intelligent Bio Solutions Inc (INBS) reported a net loss of $12.4M while operations used $11.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Intelligent Bio Solutions Inc cover its interest payments?
Intelligent Bio Solutions Inc (INBS) reported an operating loss of $12.6M against $11K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Intelligent Bio Solutions Inc?
Intelligent Bio Solutions Inc (INBS) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.